Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsClinical population pharmacokinetics and toxicodynamics of linezolid.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersPopulation pharmacokinetic analysis of piperacillin in burn patientsBroad-spectrum β-lactams in obese non-critically ill patients.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensPharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in ratsPhase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisTwo mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiPopulation Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infectionsApplications of minimal physiologically-based pharmacokinetic models.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designOptimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaBone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulationModeling the autoinhibition of clarithromycin metabolism during repeated oral administrationNew semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Pharmacokinetic evaluation of piperacillin-tazobactam.The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.Pharmacokinetics of ertapenem in colorectal tissue.Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.Dose optimization of piperacillin/tazobactam in critically ill children.Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis
P2860
Q26827380-508CEFD0-D48F-49DB-A85D-2E406C33B721Q33413269-7C38F717-BFB3-4001-9A8A-B9C177A6B737Q33676387-E38EA529-ADF7-4C63-A8D5-5E93B7F6CC78Q33798377-D414FF91-4119-48BC-B946-012F51E5C4A0Q33839225-7EAAD4FC-3B9B-4A56-836E-F039767FDB13Q34108660-7A0F28FE-06F2-4118-AE8F-AA997850C138Q34297656-DA265F16-8F91-470B-A583-0F4230C8BA75Q34381321-C9F228B4-3EEB-48BB-A281-B3B9AE07AB6FQ34501161-7F2A2743-8C5A-4AA2-BC15-B0AA9A131FC6Q34529205-0B3C1838-5835-46BF-8ADB-0131CF7BCC0BQ35005118-71DF40FA-6203-4070-9E3F-DB3FB539F8BBQ35065732-48B3F508-CCE9-4400-B688-E7DBF3F4DECEQ35168882-3F974278-78D5-44F2-93B7-1E62B577B11FQ35168931-3E8B20AB-AB9B-4D85-BC09-B9A8D527488DQ35967888-0EDE42C6-382E-4CB9-9958-F1C0637E37E7Q36076101-0F3B6078-4605-4A9C-B654-A7319B2423C5Q36171570-E21BFEA8-3067-48AD-8CCE-C75646EDEEFCQ36517093-2484E161-73CB-43D9-9D2E-B0AF6892E405Q36785827-047D8CC3-B2DA-45D5-B477-AF4B02825CBDQ36887819-97C4795E-D540-4EC7-83AA-D93A2E67558EQ37204197-D833AC36-5EAE-489F-B5BB-CF42CEC20DC6Q37247655-62699E01-8347-4805-A710-A486035413FBQ37274639-BF710C65-D7F7-4DAD-8219-A3268F58116AQ37274643-D5852B1A-8317-411B-8813-15DEBF04641DQ37333151-075368A5-C302-4967-AE4F-3290246DD64EQ37538609-D40BBAF3-623C-40F3-BFCF-13704D0D7803Q37538623-71AFB6C1-AD72-4970-BA35-BDBA867A45C7Q37642084-AB463B5E-9759-4D48-9598-970730088A94Q37773368-8FE1D280-33E2-44FC-B37C-B6BC93A50CC6Q37996075-2A6856C9-0DCA-4EFD-A61E-E7ADFA0B230EQ38040736-456255E0-61A8-4BBA-A927-9F83ED9458F6Q38077518-E89033A5-9574-4B16-AEE5-A4B2921BD047Q38479091-049B2DBE-8E18-4EA9-93BC-3CC2B664EE0BQ38625059-A37C97A4-3433-469C-8A55-5DF4B583A7F1Q38848103-D5384692-9E1B-4B0E-B30C-13B567CC2174Q39040314-B19D808F-6603-48F6-AE6B-73D0D40A86BDQ39097052-CF695ECC-B554-46F8-A199-DD27F5757341Q39170967-202B467B-A9B5-437B-A55B-EBC652DFF30EQ40237248-BBAB07BF-264C-44E0-A683-4627F843AAB6Q41063056-47BBF58C-F5AA-4A7B-A256-DB5A57A8FB41
P2860
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systematic comparison of the p ...... tients and healthy volunteers.
@ast
Systematic comparison of the p ...... tients and healthy volunteers.
@en
type
label
Systematic comparison of the p ...... tients and healthy volunteers.
@ast
Systematic comparison of the p ...... tients and healthy volunteers.
@en
prefLabel
Systematic comparison of the p ...... tients and healthy volunteers.
@ast
Systematic comparison of the p ...... tients and healthy volunteers.
@en
P2093
P2860
P356
P1476
Systematic comparison of the p ...... tients and healthy volunteers.
@en
P2093
G L Drusano
J B Bulitta
M Kinzig-Schippers
S B Duffull
P2860
P304
P356
10.1128/AAC.01477-06
P407
P577
2007-05-07T00:00:00Z